The opportunity cost of undervaluing scientific insight is having to meet global challenges reactively, not proactively. Great example:
This month, the US stock market lost two trillion dollars in market-cap due to a problem that science R&D could have preemptively solved.
That figure exceeds the sum of all funds ever received over all years since 1950 by the National Science Foundation, the NIH, and the CDC.